| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 408 | 444 | 398 | 435 | 459 | 475 | 445 | 447 | 545 | 452 | 604 | 554 | 619 | 613 | 605 | 627 | 786 | 811 | 796 | 767 | 902 | 889 | 852 | 878 | 1,010 | 1,011 | 972 |
| Expenses | 326 | 354 | 304 | 353 | 350 | 356 | 339 | 362 | 367 | 334 | 377 | 405 | 442 | 466 | 473 | 500 | 612 | 625 | 618 | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 |
| EBITDA | 82 | 90 | 94 | 81 | 109 | 119 | 106 | 85 | 178 | 119 | 227 | 149 | 177 | 146 | 133 | 127 | 174 | 186 | 178 | 168 | 238 | 251 | 231 | 215 | 286 | 281 | 263 |
| Operating Profit % | 20 % | 19 % | 20 % | 16 % | 22 % | 22 % | 21 % | 18 % | 30 % | 25 % | 31 % | 23 % | 27 % | 21 % | 21 % | 20 % | 22 % | 23 % | 22 % | 21 % | 26 % | 28 % | 26 % | 23 % | 28 % | 27 % | 26 % |
| Depreciation | 15 | 15 | 15 | 12 | 16 | 16 | 17 | 17 | 17 | 18 | 17 | 17 | 18 | 16 | 17 | 22 | 26 | 28 | 28 | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 8 | 8 | 14 | 12 | 10 | 13 | 9 | 6 | 2 | 3 |
| Profit Before Tax | 66 | 75 | 78 | 68 | 92 | 102 | 88 | 67 | 157 | 99 | 209 | 132 | 158 | 129 | 114 | 103 | 142 | 150 | 141 | 123 | 194 | 209 | 184 | 165 | 240 | 237 | 218 |
| Tax | 21 | 23 | 28 | 22 | 30 | 8 | 22 | 17 | 38 | 25 | 54 | 31 | 39 | 32 | 30 | 18 | 37 | 39 | 35 | 35 | 52 | 58 | 50 | 38 | 63 | 62 | 56 |
| Net Profit | 46 | 52 | 50 | 47 | 62 | 94 | 66 | 50 | 120 | 74 | 154 | 101 | 119 | 98 | 84 | 85 | 105 | 111 | 106 | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 163 |
| EPS in ₹ | 5.46 | 6.14 | 6.07 | 5.68 | 7.73 | 11.67 | 8.26 | 6.30 | 15.45 | 9.55 | 19.94 | 13.02 | 15.38 | 12.65 | 10.85 | 10.98 | 13.59 | 14.37 | 13.72 | 11.33 | 9.20 | 9.72 | 8.62 | 8.22 | 11.39 | 11.24 | 10.46 |
J B Chemicals and Pharmaceuticals
1,730.40
+50.75
(3.02%)
Market Cap
26,126.70 Cr
EPS
35.66
PE Ratio
41.98
Dividend Yield
0.71 %
Industry
Healthcare52 Week High
2,030.00
52 Week Low
1,433.60
PB Ratio
8.36
Debt to Equity
0.18
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
11.46 %
Net Income Growth
34.78 %
Cash Flow Change
27.97 %
ROE
14.34 %
ROCE
29.17 %
EBITDA Margin (Avg.)
18.76 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 |
| Fixed Assets | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 |
| Current Assets | 901 | 816 | 795 | 1,047 | 1,051 | 1,073 | 1,553 | 1,253 | 1,528 | 1,853 |
| Capital Work in Progress | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 |
| Investments | 367 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 |
| Other Assets | 737 | 594 | 580 | 674 | 699 | 750 | 901 | 1,299 | 1,392 | 1,525 |
| Total Liabilities | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 |
| Current Liabilities | 460 | 431 | 281 | 275 | 244 | 313 | 345 | 384 | 554 | 868 |
| Non Current Liabilities | 33 | 31 | 27 | 46 | 65 | 69 | 79 | 85 | 519 | 203 |
| Total Equity | 995 | 1,186 | 1,366 | 1,444 | 1,483 | 1,438 | 1,813 | 2,139 | 2,480 | 2,923 |
| Reserve & Surplus | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 |
| Share Capital | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 |
| Investing Activities | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 |
| Operating Activities | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 |
| Financing Activities | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -386 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 55.91 % | 55.91 % | 55.91 % | 54.00 % | 54.00 % | 54.00 % | 53.96 % | 53.95 % | 53.93 % | 53.91 % | 53.86 % | 53.83 % | 53.78 % | 53.77 % | 53.74 % | 53.66 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.05 % | 0.00 % | 11.06 % | 12.17 % | 13.63 % | 14.64 % |
| DIIs | 12.41 % | 12.32 % | 14.76 % | 16.03 % | 16.67 % | 17.52 % | 18.08 % | 18.54 % | 19.08 % | 18.65 % | 18.58 % | 17.97 % | 18.38 % | 17.62 % | 16.81 % | 16.41 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.01 % | 0.00 % |
| Public / Retail | 20.50 % | 19.69 % | 17.64 % | 18.38 % | 17.87 % | 17.37 % | 16.94 % | 16.70 % | 15.98 % | 15.66 % | 15.34 % | 15.17 % | 14.69 % | 14.38 % | 13.87 % | 13.42 % |
| Others | 11.18 % | 12.08 % | 11.70 % | 11.58 % | 11.47 % | 11.10 % | 11.02 % | 10.81 % | 11.00 % | 11.79 % | 2.17 % | 13.03 % | 2.09 % | 2.05 % | 1.94 % | 1.87 % |
| No of Share Holders | 0 | 65,715 | 70,740 | 71,788 | 64,861 | 61,314 | 60,268 | 58,629 | 56,633 | 55,965 | 60,817 | 63,230 | 63,892 | 66,953 | 62,743 | 62,081 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 5 | 1 | 2 | 5 | 11 | 16.5 | 16.5 | 17.75 | 12.25 | 0.00 |
| Dividend Yield (%) | 2.89 | 0.64 | 1.1 | 1.96 | 1.75 | 2.1 | 1.67 | 1.08 | 0.73 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
USFDA Inspection Of CompanyS API Manufacturing Facility - D9 At Panoli Gujarat
USFDA Inspection Of CompanyS Manufacturing Facility - T20 At Panoli Gujarat
DJSI (Dow Jones Sustainable Index) ESG Score Release
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation Of Schedule Of Analysts/Institutional Investors Meet
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Integrated Filing (Financial)
Board Comments On Fine Levied By The Exchange For Delayed Compliance
Intimation Of Record Date
Corporate Action-Board approves Dividend
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Unaudited Financial Results For The Quarter Ended On December 31 2024
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for (I) Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024; And
(Ii) Consideration Of Declaration Of Interim
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Presentation
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment Of Equity Shares On Exercise Of Stock Options Pursuant To Employee Stock Option Scheme - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Regulations And Disclosure Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Investor Presentation
Board Comments On Fine Levied By The Exchange For Delayed Compliance
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024
3Rd Sustainability (ESG) Report
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Capacity Addition
Closure of Trading Window
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation Of Schedule Of Analysts/Institutional Meet
Intimation Of Schedule Of Analysts/Institutional Meet
Technical Indicators
RSI(14)
Neutral 62.32
ATR(14)
Volatile 64.74
STOCH(9,6)
Overbought 86.35
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 22.33
ADX(14)
Strong Trend 26.97
UO(9)
Bearish 65.17
ROC(12)
Uptrend And Accelerating 8.68
WillR(14)
Overbought -5.45
About J B Chemicals and Pharmaceuticals
J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Website
Chairperson NameArun Duggal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
